Почетна › Рак јетре (хепатоцелуларни карцином) › Њујорк
Kliničke studije za Рак јетре (хепатоцелуларни карцином) u državi Њујорк
36 studija za Рак јетре (хепатоцелуларни карцином) traži učesnike na lokacijama u državi Њујорк.
Gradovi u državi Њујорк
Zvanični tekst studije (na engleskom)
A Phase 1/1B Study of ST-01156, a Small Molecule RBM39 Degrader, in Patients With Advanced Solid Malignancies
- Memorial Sloan Kettering Cancer Center, New York
Тражи се учесникФаза 1
Узраст 16 и старији · Оба пола · Ажурирано 12. 11. 2026. · NCT07197554Real-world Evaluation of the HistoSonics Edison System for Treatment of Liver Tumors Across Multidisciplinary Users (BOOMBOX: Master Study)
- Northwell Health, Manhasset
- NYU Langone Health, New York
- Columbia University Irving Medical Center, New York
- и још 3
Тражи се учесникОпсервациона студија
Узраст 22 и старији · Оба пола · Ажурирано 6. 11. 2026. · NCT06486454DB-1311 in Combination With BNT327 or DB-1305 in Advanced/Metastatic Solid Tumors
- USA04-0, New York
Тражи се учесникФаза 2
Узраст 18 и старији · Оба пола · Ажурирано 29. 10. 2026. · NCT06953089A Study of MGC026 in Participants With Advanced Solid Tumors
- START-New York Long Island, Lake Success
Тражи се учесникФаза 1
Узраст 18 и старији · Оба пола · Ажурирано 28. 10. 2026. · NCT06242470A Study to Evaluate ALN-BCAT in Patients With Hepatocellular Carcinoma
- Clinical Trial Site, New York
Тражи се учесникФаза 1
Узраст 18 и старији · Оба пола · Ажурирано 27. 10. 2026. · NCT06600321A Study to Evaluate the Efficacy and Safety of Ifinatamab Deruxtecan (I-DXd) in Subjects With Recurrent or Metastatic Solid Tumors (IDeate-PanTumor02)
- NYU Langone Health, New York
- Icahn School of Medicine At Mount Sinai Prime, New York
- Clinical Research Alliance, Inc, Westbury
- и још 1
Тражи се учесникФаза 1/2
Узраст 18 и старији · Оба пола · Ажурирано 26. 10. 2026. · NCT06330064A Phase 1 Study of the Safety and Tolerability of CTX-10726
- START New York, Lake Success
Тражи се учесникФаза 1
Узраст 18 и старији · Оба пола · Ажурирано 23. 10. 2026. · NCT07419841A Study to Evaluate the Safety and Tolerability of Pumitamig Alone or In Combination With Ipilimumab in Participants With First-Line Advanced or Unresectable Hepatocellular Carcinoma (HCC) (ROSETTA HCC-206)
- Laura and Isaac Perlmutter Cancer Center at NYU Langone, Mineola
Тражи се учесникФаза 1/2
Узраст 18 и старији · Оба пола · Ажурирано 23. 10. 2026. · NCT07291076A Study of TTI-101 as Monotherapy and in Combination in Participants With Locally Advanced or Metastatic, and Unresectable Hepatocellular Carcinoma
- Memorial Sloan Kettering Cancer Center - New York, New York
Тражи се учесникФаза 1/2
Узраст 18 и старији · Оба пола · Ажурирано 22. 10. 2026. · NCT05440708A Phase 1/2a Study of DB-1311/BNT324 in Advanced/Metastatic Solid Tumors
- Research Site 107, New York
Тражи се учесникФаза 1/2
Узраст 18 и старији · Оба пола · Ажурирано 21. 10. 2026. · NCT05914116Safety, PK and Efficacy of QXL138AM in Patients With Solid Tumors and Multiple Myeloma
- New York Cancer & Blood Specialists, New York
- University of Rochester - Wilmot Cancer Institute, Rochester
Тражи се учесникФаза 1
Узраст 18 и старији · Оба пола · Ажурирано 20. 10. 2026. · NCT06582017Safety and Preliminary Anti-Tumor Activity of TYRA-430 in Advanced Hepatocellular Carcinoma and Other Solid Tumors With Activating FGF/FGFR Pathway Aberrations
- Columbia University Irving Medical Center, New York
Тражи се учесникФаза 1
Узраст 18 и старији · Оба пола · Ажурирано 14. 10. 2026. · NCT06915753Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400
- Memorial Sloan Kettering Cancer Center - New York - York Avenue /ID# 255132, New York
Тражи се учесникФаза 1
Узраст 18 и старији · Оба пола · Ажурирано 14. 10. 2026. · NCT06084481A Study of Imaging, Blood, and Tissue Samples to Guide Treatment of Colon Cancer and Related Liver Tumors
- Memorial Sloan Kettering Commack, Commack
- Memorial Sloan Kettering Westchester, Harrison
- Memorial Sloan Kettering Cancer Center, New York
Тражи се учесникОпсервациона студија
Узраст 18 и старији · Оба пола · Ажурирано 13. 10. 2026. · NCT03432806A Study to Evaluate ARV-6723 Alone and With Pembrolizumab in Participants With Advanced Solid Tumors
- Clinical Trial Site, New York
Тражи се учесникФаза 1/2
Узраст 18 и старији · Оба пола · Ажурирано 13. 10. 2026. · NCT07749586Phase III Study of Rilvegostomig in Combination With Bevacizumab With or Without Tremelimumab as First-line Treatment of Hepatocellular Carcinoma
- Research Site, New York
- Research Site, New York
- Research Site, New York
Тражи се учесникФаза 3
Узраст 18 и старији · Оба пола · Ажурирано 13. 10. 2026. · NCT06921785FOG-001 in Locally Advanced or Metastatic Solid Tumors
- Memorial Sloan Kettering Cancer Center, New York
Тражи се учесникФаза 1/2
Узраст 18 и старији · Оба пола · Ажурирано 7. 10. 2026. · NCT05919264A Study of ZW251 in Participants With Advanced Solid Tumors
- Memorial Sloan Kettering Cancer Center, New York
Тражи се учесникФаза 1
Узраст 18 и старији · Оба пола · Ажурирано 5. 10. 2026. · NCT07164313Study of Zanzalintinib in Combination With Immuno-Oncology or Other Agents in Participants With Solid Tumors
- Exelixis Clinical Site #60, New York
- Exelixis Clinical Site #6, New York
- Exelixis Clinical Site #76, Syracuse
Тражи се учесникФаза 1
Узраст 18 и старији · Оба пола · Ажурирано 1. 10. 2026. · NCT05176483Study of the Theranostic Pair RYZ811 (Diagnostic) and RYZ801 (Therapeutic) to Identify and Treat Subjects With GPC3+ (Glypican-3) Unresectable HCC
- Research Facility, New York
Тражи се учесникФаза 1/2
Узраст 18 и старији · Оба пола · Ажурирано 28. 9. 2026. · NCT06726161National Liver Cancer Screening Trial
- The Feinstein Institutes, Northwell Health, Inc., Manhasset
Тражи се учесникФаза 4
Узраст од 18 до 85 · Оба пола · Ажурирано 25. 9. 2026. · NCT06084234A Phase 1/2 Study of BGB-B2033, Alone or in Combination With Tislelizumab With or Without Bevacizumab, in Participants With Advanced or Metastatic Solid Tumors
- Memorial Sloan Kettering Cancer Center Mskcc, New York
Тражи се учесникФаза 1/2
Узраст 18 и старији · Оба пола · Ажурирано 16. 9. 2026. · NCT06427941GPC3-Targeted T-Cell Therapy (ECT204) in Adults With Advanced HCC
- Montefiore Einstein Comprehensive Cancer Center, The Bronx
Тражи се учесникФаза 1/2
Узраст 18 и старији · Оба пола · Ажурирано 10. 9. 2026. · NCT04864054Tegavivint for the Treatment of Recurrent or Refractory Solid Tumors, Including Lymphomas and Desmoid Tumors
- NYP/Columbia University Medical Center/Herbert Irving Comprehensive Cancer Center, New York
Тражи се учесникФаза 1/2
12 Months – 30 Years · Оба пола · Ажурирано 25. 8. 2026. · NCT04851119Testing Immunotherapy With or Without Stereotactic Body Radiation Therapy in Patients With Advanced Liver Cancer, HELIO-RT Trial
- Northwell Health/Center for Advanced Medicine, Lake Success
- Mount Sinai Hospital, New York
- Montefiore Medical Center-Einstein Campus, The Bronx
- и још 1
Тражи се учесникФаза 3
Узраст 18 и старији · Оба пола · Ажурирано 17. 8. 2026. · NCT07166406HepQuant: Study to Assess the Role of Blood-based Biomarkers and Quantitative MR Imaging for Patients Receiving Radiation Therapy for Liver Cancer
- Montefiore Medical Center, The Bronx
Тражи се учесник
Узраст 18 и старији · Оба пола · Ажурирано 11. 8. 2026. · NCT06899152Atezolizumab in Combination With a Multi-Kinase Inhibitor for the Treatment of Unresectable, Locally Advanced, or Metastatic Liver Cancer
- Roswell Park Cancer Institute, Buffalo
Тражи се учесникФаза 2
Узраст 18 и старији · Оба пола · Ажурирано 4. 8. 2026. · NCT05168163Atezolizumab and Bevacizumab in Combination With Y^90 Radioembolization in HCC for Liver Transplant
- Icahn School of Medicine at Mount Sinai, New York
Тражи се учесникФаза 4
Узраст 18 и старији · Оба пола · Ажурирано 28. 7. 2026. · NCT07059494A Study to Assess the Efficacy and Safety of FORE8394 in Participants With Cancer Harboring BRAF Alterations
- Columbia University Irving Medical Center, New York
- Memorial Sloan Kettering Cancer Center, New York
Тражи се учесникФаза 2
Узраст 8 и старији · Оба пола · Ажурирано 27. 7. 2026. · NCT05503797Preventing Liver Cancer Mortality Through Imaging With Ultrasound vs. MRI
- VA NY Harbor Healthcare System, New York, NY, New York
- James J. Peters VA Medical Center, Bronx, NY, The Bronx
Тражи се учесник
Узраст од 18 до 75 · Оба пола · Ажурирано 17. 6. 2026. · NCT05486572Study of RP2 in Combination With Second-line Therapy in Patients With Locally Advanced or Metastatic HCC
- Roswell Park Comprehensive Cancer Center, Buffalo
- Montefiore Medical CenterMontefiore Medical Park, The Bronx
Тражи се учесникФаза 2
Узраст 18 и старији · Оба пола · Ажурирано 2. 4. 2026. · NCT05733598Tislelizumab Consolidation After Liver-Directed Therapy for Hepatocellular Carcinoma
- Montefiore Medical Center, The Bronx
Тражи се учесникФаза 2
Узраст 18 и старији · Оба пола · Ажурирано 20. 1. 2026. · NCT05366829HOPE Against Cancer Recurrence in HCC
- Rutgers New Jersey Medical School (New York), New York
Тражи се учесникФаза 4
Узраст 18 и старији · Оба пола · Ажурирано 16. 12. 2025. · NCT06717919SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry
- Massive Bio SYNERGY-AI site, Buffalo
- Massive Bio SYNERGY-AI site, Hempstead
- Massive Bio SYNERGY-AI site, Manhasset
- и још 2
Тражи се учесникОпсервациона студија
Сви узрасти · Оба пола · Ажурирано 28. 10. 2025. · NCT03452774The Dragon PLC Trial (DRAGON-PLC)
- Memorial Sloan Kettering Cancer Center, New York
Тражи се учесник
Узраст 18 и старији · Оба пола · Ажурирано 15. 5. 2025. · NCT06914648A Study to Evaluate the Safety and Therapeutic Activity of GI-102 As a Single Agent and in Combination with Conventional Anti-cancer Drugs, Pembrolizumab or Trastuzumab Deruxtecan(T-DXd) in Patients with Advanced Solid Tumors (KEYNOTE-G08)
- Memorial Sloan-Kettering Cancer Center, New York
Тражи се учесникФаза 1/2
Узраст 18 и старији · Оба пола · Ажурирано 25. 11. 2024. · NCT05824975Sa sajta ClinicalTrials.gov, podaci preuzeti 15. 11. 2026.. Svaka studija ima svoje kriterijume za uključivanje; tim studije odlučuje ko može da učestvuje.